Novel antimicrobial inhibitors of Biotin Protein Ligase (BPL), which incorporate biotin, are described. The inhibitors have a structure that inhibit the essential metabolic enzyme BPL of pathogens and have been shown to be stable in whole blood and effective at reducing BPL activity in acceptable concentrations. The described compounds have shown to be effective against, for example, Staphylococcus aureus and compare favourably against erythromycin